ASH 2020 | Exciting AML updates at ASH 2020
Amir Fathi
• 24 Oct 2020
Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA, discusses some of the exciting updates in acute myeloid leukemia (AML) at this year’s ASH meeting. Specifically discussed are menin inhibitors, ‘all oral’ combinations such as venetoclax and gilteritinib and various other venetoclax combinations such as as those including, CPX-351 or hypomethylating agents. Finally, current efforts in finding new targets are outlined. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
